<DOC>
	<DOCNO>NCT00188773</DOCNO>
	<brief_summary>A prolonged elevation plasma free fatty acid ( FFA ) impair glucose stimulate insulin secretion . The concept fatty acid impairment glucose stimulate insulin secretion ( lipotoxicity ) well accept . Increased free fatty acid flux adipose tissue non-adipose tissue , result abnormality fat metabolism , participate amplifies many metabolic derangement characteristic insulin resistance syndrome type 2 diabetes . Lipotoxicity also likely play important role progression normal glucose tolerance fast hyperglycemia conversion frank type 2 diabetes insulin resistant individual . This area research focus determine mechanism whereby FFAs impair b-cell function . There evidence suggest lipotoxicity could mediate induction reactive oxygen specie ( ROS ) . N-acetylcysteine ( NAC ) know potent antioxidant use experimentally number medical condition human protective antioxidant effect . The investigator plan administer NAC orally humans 48 hour examine effect antioxidant therapy ameliorate deleterious effect FFAs pancreatic beta cell function . NAC currently approve treatment acetaminophen overdose also use mucolytic agent . The investigator use NAC antioxidant determine whether protects pancreatic beta cell toxic effect FFAs , outline detailed study protocol . This proof-of-principle study design develop n-acetylcysteine therapeutic use .</brief_summary>
	<brief_title>Mechanism Fatty Acid-Induced Impairment Glucose-Stimulated Insulin Secretion</brief_title>
	<detailed_description>Free fatty acid elevate approximately 2-fold 48 hour intravenous infusion Intralipid heparin . 15 abdominally obese insulin resistant , otherwise healthy , non-diabetic men study three occasion , random order , 4 week apart . We choose study abdominally obese , insulin resistant individual rather lean healthy control previously show individual susceptible lipotoxicity therefore likely see difference intervention difference indeed exist . Informed write consent obtain participant accordance guideline Human Subjects Review Committee University Health Network . Subjects hospitalize Metabolic Investigation Unit ( MIU ) Toronto General Hospital three study , perform random order 4 6 week apart . On one occasion saline control study perform , second occasion Intralipid ( 20 % solution @ 40ml/hr ) heparin ( 250u/hr ) infuse 48 hour previously describe third occasion NAC administer orally concurrently Intralipid heparin . The dose NAC recommend acetaminophen overdose . An initial loading dose 140mg/kg NAC follow maintenance dose 70mg/kg every 4 hour 48 hour infusion Intralipid heparin . On day three , test glucose-stimulated insulin secretion ( GSIS ) occur outline . Subjects provide isocaloric diet consist 50 % calorie derive carbohydrate , 30 % fat 20 % protein 48 hour infusion fast midnight test pancreatic beta cell function day three .</detailed_description>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Acetylcysteine</mesh_term>
	<mesh_term>N-monoacetylcystine</mesh_term>
	<mesh_term>Soybean oil , phospholipid emulsion</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>The following criterion use selection insulin resistant nondiabetic men age 3565 year : 1 . Written inform consent obtain 2 . Body mass index ( BMI ) &gt; 27 kg/m2 3 . Fasting triglyceride &gt; 2 mmol/l &lt; 5 mmol/l 4 . Waist circumference &gt; 90 cm 5 . Fasting blood glucose &lt; 7 mmol/l 6 . In order keep number study subject minimum ( n=15 ) , view cost laborintensive metabolic study , investigator study male 35 65 year age . This allow study homogeneous group subject possible . If significant protective effect NAC beta cell function detect , study woman use similar protocol later stage . 7 . Hemoglobin 130 g/L 1 . Patient history hepatitis/hepatic disease active within previous two year 2 . Any significant active ( past 12 month ) disease gastrointestinal , pulmonary , neurological , renal ( Cr &gt; 1.5 mg/dL ) genitourinary , hematological system , severe uncontrolled treated untreated hypertension ( sit diastolic BP &gt; 100 systolic &gt; 180 ) proliferative retinopathy 3 . Fasting blood glucose &gt; 7 mmol/l know diabetes 4 . Any history MI clinically significant , active , cardiovascular history include history arrhythmias conduction delay ECG , unstable angina , decompensated heart failure 5 . Any laboratory value : AST &gt; 2x ULN ; ALT &gt; 2x ULN TSH &gt; 6 mU/l 6 . Known suspected allergy medication history multiple and/or severe allergy drug food history severe anaphylactic reaction 7 . Current addiction alcohol substance abuse determine investigator 8 . Mental incapacity , unwillingness language barrier preclude adequate understanding cooperation 9 . Any lipid lowering hypoglycemic agent 10 . Previous history asthma 11 . Will donate blood three month prior three month post study procedure</criteria>
	<gender>Male</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>n-acetylcysteine ,</keyword>
	<keyword>free fatty acid ,</keyword>
	<keyword>glucose stimulate insulin secretion ,</keyword>
	<keyword>insulin resistance syndrome</keyword>
	<keyword>antioxidant therapy</keyword>
	<keyword>Insulin Resistance</keyword>
</DOC>